Inventor · disambiguated record
Rhett M. Schiffman
Also filed as: SCHIFFMAN RHETT · SCHIFFMAN RHETT M · SCHIFFMAN RHETT MEAD
39 granted patents·66 pending applications·314 citations·filing 2003–2025
98Inventor score
Top patents by PatentIndex Score
105 records- 0197US8933120B2Enhanced bimatoprost ophthalmic solutionALLERGAN INC·Filed 2013·Granted Jan 13, 2015·13 cites·20 claims
- 0297US8647659B2Intracameral sustained release therapeutic agent implantsROBINSON MICHAEL R·Filed 2011·Granted Feb 11, 2014·46 cites·5 claims
- 0397US8309605B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2010·Granted Nov 13, 2012·20 cites·21 claims
- 0497US8278353B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2012·Granted Oct 2, 2012·16 cites·30 claims
- 0597US7851504B2Enhanced bimatoprost ophthalmic solutionALLERGAN INC·Filed 2005·Granted Dec 14, 2010·24 cites·3 claims
- 0696US8299118B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2012·Granted Oct 30, 2012·27 cites·30 claims
- 0795US8586630B2Enhanced bimatoprost ophthalmic solutionALLERGAN INC·Filed 2012·Granted Nov 19, 2013·8 cites·20 claims
- 0894US10278919B2Intracameral sustained release therapeutic agent implantsALLERGAN INC·Filed 2016·Granted May 7, 2019·10 cites·13 claims
- 0994US7842714B2Ketorolac tromethamine compositions for treating ocular painALLERGAN INC·Filed 2009·Granted Nov 30, 2010·23 cites·3 claims
- 1093US9504696B2Intracameral sustained release therapeutic agent implantsALLERGAN INC·Filed 2015·Granted Nov 29, 2016·8 cites·14 claims
- 1193US9061065B2Intracameral sustained release therapeutic agent implantsALLERGAN INC·Filed 2013·Granted Jun 23, 2015·15 cites·6 claims
- 1293US8772338B2Enhanced bimatoprost ophthalmic solutionALLERGAN INC·Filed 2013·Granted Jul 8, 2014·5 cites·20 claims
- 1393US8524777B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2012·Granted Sep 3, 2013·7 cites·28 claims
- 1491US9241918B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2010·Granted Jan 26, 2016·5 cites·8 claims
- 1591US8338479B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2009·Granted Dec 25, 2012·10 cites·16 claims
- 1690US11147855B2Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humourCELLA THERAPEUTICS LLC·Filed 2019·Granted Oct 19, 2021·3 cites·19 claims
- 1790US9155716B2Enhanced bimatoprost ophthalmic solutionALLERGAN INC·Filed 2013·Granted Oct 13, 2015·4 cites·12 claims
- 1889US9061034B2Preservative free bimatoprost and timolol solutionsALLERGAN INC·Filed 2013·Granted Jun 23, 2015·6 cites·8 claims
- 1989US7745400B2Prevention and treatment of ocular side effects with a cyclosporinFEINERMAN GREGG·Filed 2006·Granted Jun 29, 2010·11 cites·11 claims
- 2088US8933127B2Enhanced bimatoprost ophthalmic solutionCHANG CHIN-MING·Filed 2012·Granted Jan 13, 2015·3 cites·21 claims
- 2187US7557082B2Treatment with cyclosporin AALLERGAN INC·Filed 2007·Granted Jul 7, 2009·7 cites·7 claims
- 2287US2024197657A1Ketorolac tromethamine compositions for treating or preventing ocular painALLERGAN INC·Filed 2023·Application pending·0 cites
- 2387US2024148643A1Intracameral sustained release therapeutic agent implantsALLERGAN INC·Filed 2023·Application pending·0 cites
- 2486US10058560B2Preservative free bimatoprost and timolol solutionsALLERGAN INC·Filed 2017·Granted Aug 28, 2018·2 cites·8 claims
- 2586US9561178B2Cyclosporin compositionsGRAHAM RICHARD S·Filed 2007·Granted Feb 7, 2017·5 cites·10 claims
- 2685US12128104B2Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2020·Granted Oct 29, 2024·1 cites·17 claims
- 2784US9937188B2Non-irritating testosterone emulsionsALLERGAN INC·Filed 2014·Granted Apr 10, 2018·5 cites·23 claims
- 2884US9763958B2Preservative free bimatoprost and timolol solutionsALLERGAN INC·Filed 2015·Granted Sep 19, 2017·2 cites·5 claims
- 2984US8207129B2Treatment with cyclosporin ASCHIFFMAN RHETT M·Filed 2009·Granted Jun 26, 2012·6 cites·6 claims
- 3083US9192571B2Ketorolac tromethamine compositions for treating or preventing ocular painFARNES ELDON Q·Filed 2009·Granted Nov 24, 2015·4 cites·26 claims
- 3182US12029683B2Ocular implant and delivery systemALCON INC·Filed 2019·Granted Jul 9, 2024·2 cites·7 claims
- 3281US8536190B2Treating unwanted ocular conditions using an ascomycin macrolactamSCHIFFMAN RHETT M·Filed 2008·Granted Sep 17, 2013·1 cites·6 claims
- 3381US2023181497A1Ketorolac tromethamine compositions for treating or preventing ocular painALLERGAN INC·Filed 2022·Application pending·0 cites
- 3479US9839667B2Prevention and treatment of ocular side effects with a cyclosporinALLERGAN INC·Filed 2013·Granted Dec 12, 2017·2 cites·6 claims
- 3579US9248135B2Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of useALLERGAN INC·Filed 2013·Granted Feb 2, 2016·3 cites·23 claims
- 3679US2025090670A1Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 3779US2020121593A1Intracameral sustained release therapeutic agent implantsALLERGAN INC·Filed 2019·Application pending·0 cites
- 3879US2025000790A1Ketorolac compositions for corneal wound healingALLERGAN INC·Filed 2024·Application pending·0 cites
- 3978US9579328B2Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of useALLERGAN INC·Filed 2016·Granted Feb 28, 2017·2 cites·14 claims
- 4078US8501174B2Prevention and treatment of ocular side effects with a cyclosporinFEINERMAN GREGG·Filed 2010·Granted Aug 6, 2013·4 cites·4 claims
- 4177US2015087713A1Enhanced bimatoprost ophthalmic solutionALLERGAN INC·Filed 2014·Application pending·0 cites
- 4277US2022202829A1Non-irritating testosterone emulsionsALLERGAN INC·Filed 2021·Application pending·0 cites
- 4377US2023158161A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 4477US2022409693A1Cyclosporin compositionsALLERGAN INC·Filed 2022·Application pending·0 cites
- 4575US12268662B2Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effectsVISUS THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·11 claims
- 4675US2021169780A1Intracameral sustained release therapeutic agent implantsALLERGAN INC·Filed 2020·Application pending·0 cites
- 4775US2025281432A1Ketorolac tromethamine compositions for treating or preventing ocular painALLERGAN INC·Filed 2025·Application pending·0 cites
- 4874US2022339237A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 4972US2021113588A1Non-irritating testosterone emulsionsALLERGAN INC·Filed 2020·Application pending·0 cites
- 5072US2021121534A1Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
Showing the top 50 of 105 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Rhett M. Schiffman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →